Preclinical and Phase I Results of Decitabine in Combination with Midostaurin (PKC412) for Newly Diagnosed Elderly or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia

To determine the preclinical activity, clinical maximum tolerated dose (MTD), and recommended phase II dose of midostaurin (MS) combined either sequentially or concurrently with intravenous decitabine (DAC) in newly diagnosed patients 60 years or older or relapsed/refractory adult patients (18 years or older) with acute myeloid leukemia (AML).

[1]  F. Giles,et al.  Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia , 2012, Leukemia.

[2]  A. Rademaker,et al.  Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia. , 2012, Leukemia research.

[3]  T. Down,et al.  Genome Wide Analysis of Acute Myeloid Leukemia Reveal Leukemia Specific Methylome and Subtype Specific Hypomethylation of Repeats , 2012, PloS one.

[4]  B. Rini,et al.  p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. , 2012, Seminars in oncology.

[5]  M. McDevitt.  Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies. , 2012, Seminars in oncology.

[6]  C. O'keefe,et al.  CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors , 2012, Leukemia.

[7]  G. Roboz.  Novel approaches to the treatment of acute myeloid leukemia. , 2011, Hematology. American Society of Hematology. Education Program.

[8]  Hongwei Ma,et al.  Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1. , 2011, Blood.

[9]  J. Scandura,et al.  Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. , 2011, Blood.

[10]  A. Fathi,et al.  FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations. , 2011, The oncologist.

[11]  H. Kantarjian,et al.  FLT3 inhibitors in the treatment of acute myeloid leukemia , 2011, Cancer.

[12]  M. Levis.  FLT3/ITD AML and the law of unintended consequences. , 2011, Blood.

[13]  B. Smith,et al.  FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. , 2011, Blood.

[14]  H. Kohrt,et al.  Acute myeloid leukaemia in the elderly: a review , 2011, British journal of haematology.

[15]  Torsten Haferlach,et al.  Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  H. Kantarjian,et al.  Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. , 2010, Blood.

[17]  M. Tallman,et al.  Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis , 2010, Cancer.

[18]  M. Tallman,et al.  How I treat acute myeloid leukemia. , 2010, Blood.

[19]  E. Estey,et al.  Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  G. Hortobagyi,et al.  Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer. , 2010, Cancer research.

[21]  C. Bloomfield,et al.  Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine , 2010, Proceedings of the National Academy of Sciences.

[22]  Kathleen M Murphy,et al.  FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. , 2010, Blood.

[23]  H. Dombret,et al.  Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Dipersio,et al.  Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Gabrilove,et al.  Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Vignetti,et al.  Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Amadori.  New agents for the treatment of acute myeloid leukemia: midostaurin , 2009 .

[28]  E. Lam,et al.  BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3. , 2009, Blood.

[29]  H. Döhner,et al.  Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment in All Cytogenetic Subgroups of Older AML Patients: Results of the FR00331 Multicenter Phase II Study. , 2007 .

[30]  R. Hills,et al.  A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment , 2007, Cancer.

[31]  C. Bloomfield,et al.  Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Susan O'Brien,et al.  Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome: , 2006, Cancer.

[33]  G. Mufti,et al.  Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Woodgett.  Recent advances in the protein kinase B signaling pathway. , 2005, Current opinion in cell biology.

[35]  Srinivas Annavarapu,et al.  Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. , 2005, Blood.

[36]  F. Debierre-Grockiego.  Anti-apoptotic role of STAT5 in haematopoietic cells and in the pathogenesis of malignancies , 2004, Apoptosis.

[37]  P. Atadja,et al.  Superior Activity of the Combination of Histone Deacetylase Inhibitor LAQ824 and the FLT-3 Kinase Inhibitor PKC412 against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3 , 2004, Clinical Cancer Research.

[38]  A. Scuto,et al.  Cotreatment with 17-Allylamino-Demethoxygeldanamycin and FLT-3 Kinase Inhibitor PKC412 Is Highly Effective against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3 , 2004, Cancer Research.

[39]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  C. Rosenfeld,et al.  Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies. , 2003, Current opinion in investigational drugs.

[41]  K. Murphy,et al.  Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. , 2003, The Journal of molecular diagnostics : JMD.

[42]  F. Appelbaum,et al.  Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. , 2002, Blood.

[43]  C. Earle,et al.  The outcomes and costs of acute myeloid leukemia among the elderly. , 2002, Archives of internal medicine.

[44]  Doriano Fabbro,et al.  Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. , 2002, Cancer cell.

[45]  A. Harris,et al.  Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  F. Appelbaum,et al.  A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). , 1998, Blood.

[47]  J. Yates,et al.  Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. , 1973, Cancer chemotherapy reports.

[48]  W. Hiddemann,et al.  Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  M. Patnaik,et al.  Anthracycline dose intensification in acute myeloid leukemia. , 2009, The New England journal of medicine.

[50]  E. Estey,et al.  Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 , 2004 .

[51]  F. Appelbaum,et al.  A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). , 1998, Blood.

[52]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.